EXHIBIT 99.1
| CONTACT: |
| Ben Stephen |
| Director, Investor Relations |
| 703-904-5539 |
| bstephen@quadramed.com |
| David L. Piazza |
| Vice President, Finance |
| 703-742-5312 |
| dpiazza@quadramed.com |
QUADRAMED ANNOUNCES ISSUANCE of
$100 MILLION CONVERTIBLE PREFERRED STOCK
Reston, Virginia – (June 17, 2004) QuadraMed® Corporation (OTCBB:QMDC.OB) announced today that it has completed the issuance of $100 million of convertible preferred stock in a private, unregistered offering to “qualified institutional buyers” pursuant to Rule 144A under the Securities Act of 1933. The company had previously announced on June 10, 2004 its intention to issue $94 million of such Preferred Stock, but the amount sold was increased as a result of strong demand for the shares. The offering was managed by the investment banking firm, Philadelphia Brokerage Corporation, with J. Giordano Securities Group assisting in the placement of the shares.
The preferred stock was sold for $25 per share; is entitled to quarterly dividends of $0.34 (5.5% per annum); and is convertible into shares of common stock of the Company at a price of $3.40. QuadraMed plans to use approximately $94 million of the net proceeds of the offering to repurchase all of its 10% senior secured notes due 2008, and all of its 5.25% convertible debentures due 2005, together with accrued interest, and related redemption premiums and transactions costs; with the remainder being used for general corporate purposes.
“Once again, the investment community has given QuadraMed a significant vote of confidence by recognizing the strength and potential of the Company,” said QuadraMed Chairman and CEO, Lawrence P. English. “We believe that eliminating the debt from our balance sheet will strengthen our competitive position, and allow us to continue to execute our strategy to increase market share, better serve our customers, and increase shareholder value” he added.
Further details with respect to the preferred stock transaction is available in the Company’s’ Form 8-K filed this date with the Securities and Exchange Commission.
This announcement is neither an offer to sell nor a solicitation to buy any securities and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful. The securities have not been registered under the Securities Act of 1933, or any state securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act of 1933 and applicable state laws.
About QuadraMed Corporation
QuadraMed is dedicated to improving healthcare delivery by providing innovative healthcare information technology and services. From clinical and patient information management to revenue cycle and health information management, QuadraMed delivers real-world solutions that help healthcare professionals deliver outstanding patient care with optimum efficiency. Behind our products and services is a staff of more than 850 professionals whose experience and dedication to service has earned QuadraMed the trust and loyalty of customers at more than 1,900 healthcare provider facilities. To find out more about QuadraMed, visit www.quadramed.com.
Cautionary Statement on Risks Associated with QuadraMed’s Forward-Looking Statements
This press release contains forward-looking statements by QuadraMed within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. The words “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “may,” “should,” “could,” and similar expressions are intended to identify such statements. Forward-looking statements are not guarantees of future performance and are to be interpreted only as of the date on which they are made. QuadraMed undertakes no obligation to update or revise any forward-looking statement except as required by law. QuadraMed advises investors that it discusses risk factors and uncertainties that could cause QuadraMed’s actual results to differ from forward-looking statements in its periodic reports filed with the Securities and Exchange Commission (“SEC”).
QuadraMed’s SEC filings can be accessed through the Investor Relations section of our website, www.quadramed.com, or through the SEC’s EDGAR Database atwww.sec.gov (QuadraMed has EDGAR CIK No. 0001018833).
Note to editors: QuadraMed is a registered trademark of QuadraMed Corporation. All other trademarks are the property of their respective owners.
###